<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520035</url>
  </required_header>
  <id_info>
    <org_study_id>CAMRE-CHEM-01</org_study_id>
    <nct_id>NCT04520035</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell</brief_title>
  <official_title>A Prospective, Single Arm, Single Center, Phase II Clinical Trial of Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single arm, single center, phase II clinical trial of neoadjuvant chemotherapy&#xD;
      with camrelizumab in locally advanced esophageal squamous cell,to evaluate the progression&#xD;
      free survival&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate (pCR)</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle (each cycle is 21 days)</time_frame>
    <description>Pathological complete response rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>PFS</condition>
  <arm_group>
    <arm_group_label>neoadjuvant chemotherapy with camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel and cisplatin&#xD;
Carilizumab 200 mg, every 3 weeks, 2 cycles.&#xD;
Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles&#xD;
Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>camrelizumab</intervention_name>
    <description>Carilizumab 200 mg, every 3 weeks, 2 cycles.Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles</description>
    <arm_group_label>neoadjuvant chemotherapy with camrelizumab</arm_group_label>
    <other_name>Paclitaxel</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles</description>
    <arm_group_label>neoadjuvant chemotherapy with camrelizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant Chemotherapy</intervention_name>
    <description>Neoadjuvant Chemotherapy</description>
    <arm_group_label>neoadjuvant chemotherapy with camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. The age ranged from 18 to 75 years 2. Middle or lower thoracic esophageal carcinoma 3.&#xD;
        Gastroscopy showed squamous cell carcinoma 4. The clinical stage was c-txn1-3m0 5. ECOG&#xD;
        score was 0-1 6. Can eat semifluid 7. Weight loss less than 20% in 6 months 8. Sign the&#xD;
        consent form before treatment 9. One week before enrollment, the organ function level&#xD;
        reached the following standards:&#xD;
&#xD;
          1. Bone marrow function: hemoglobin ≥ 100g / L, WBC ≥ 4.0 * 10 ^ 9 / L, neutrophil count&#xD;
             ≥ 1.8 * 10 ^ 9 / L, platelet count ≥ 100 * 10 ^ 9 / L;&#xD;
&#xD;
          2. Liver: serum total bilirubin level ≤ 1.5 times normal upper limit value, aspartate&#xD;
             aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 times normal upper&#xD;
             limit value;&#xD;
&#xD;
          3. Kidney: serum creatinine level is lower than 1.5 times of normal upper limit value or&#xD;
             creatinine clearance rate ≥ 60ml / min, urea nitrogen ≤ 200mg / L;&#xD;
&#xD;
          4. Blood glucose: within the normal range and / or patients with diabetes are under&#xD;
             treatment, but the blood glucose is controlled in a stable state;&#xD;
&#xD;
          5. Lung function: baseline FEV1 should be at least 2L; if the baseline FEV1 &lt; 2L, it&#xD;
             should be evaluated by surgical experts, and FEV1 &gt; 800ml after surgery should be&#xD;
             predicted;&#xD;
&#xD;
          6. Cardiac function: no myocardial infarction within 1 year; no unstable angina pectoris;&#xD;
             no symptomatic severe arrhythmia; no cardiac insufficiency.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The pathological findings were complex squamous cell carcinoma, including squamous&#xD;
             adenocarcinoma, squamous cell carcinoma, carcinosarcoma, sarcomatoid carcinoma, etc&#xD;
&#xD;
          2. He had a history of subtotal gastrectomy&#xD;
&#xD;
          3. Patients with secondary primary cancer at the same time&#xD;
&#xD;
          4. The patients with distant metastasis indicated by imaging before treatment&#xD;
&#xD;
          5. Except for skin basal cell carcinoma, skin squamous cell carcinoma and / or cervical&#xD;
             carcinoma in situ after effective treatment&#xD;
&#xD;
          6. Patients who have received chemoradiotherapy in the past&#xD;
&#xD;
          7. There were signs of esophageal perforation&#xD;
&#xD;
          8. Pregnant women of childbearing age&#xD;
&#xD;
          9. The patient has any active autoimmune disease or history of autoimmune disease (such&#xD;
             as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis,&#xD;
             myocarditis, nephritis, etc.)&#xD;
&#xD;
         10. There are patients with the following active infectious diseases, including active&#xD;
             pulmonary tuberculosis, active hepatitis B (HBV DNA ≥ 500 IU / ml), hepatitis C&#xD;
             (hepatitis C antibody positive, and HCV-RNA higher than the detection limit of the&#xD;
             analysis method), and known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
         11. Those who are known to have bleeding diseases or other uncontrollable diseases and are&#xD;
             unable to receive surgical treatment&#xD;
&#xD;
         12. Findings of physical examination or clinical trials that the researchers believe may&#xD;
             interfere with the results or increase the risk of treatment complications for&#xD;
             patients&#xD;
&#xD;
         13. Function of each organ of the patient:Previous interstitial lung disease, drug-induced&#xD;
             interstitial disease, radiation pneumonitis requiring hormone therapy, or any active&#xD;
             interstitial lung disease with clinical evidence, CT scan at baseline found the&#xD;
             presence of idiopathic pulmonary fibrosis; uncontrolled massive pleural effusion or&#xD;
             pericardial effusion;&#xD;
&#xD;
         14. Unstable systemic concomitant diseases (active infection, moderate to severe chronic&#xD;
             obstructive pulmonary disease, poorly controlled hypertension, unstable angina&#xD;
             pectoris, congestive heart failure, myocardial infarction within 6 months, severe&#xD;
             mental disorders requiring drug control, liver, kidney or other metabolic diseases,&#xD;
             neuropsychiatric diseases such as Alzheimer's disease);&#xD;
&#xD;
         15. Poor gastrointestinal function, absorption syndrome and active peptic ulcer;&#xD;
&#xD;
         16. Have received any of the following treatments:&#xD;
&#xD;
        1) Have received anti-PD-1 or anti-PD-L1 antibody treatment in the past; 2) Received any&#xD;
        research drug within 4 weeks before the first use of the study drug; 3) At the same time,&#xD;
        they were enrolled in another clinical study, unless it was an observational (non&#xD;
        intervention) clinical study or an intervention clinical study follow-up; 4) Have received&#xD;
        any anti-tumor treatment related to esophageal cancer, including but not limited to&#xD;
        radiotherapy, chemotherapy, surgery, ESD, EMR, immunotherapy, targeted therapy, and&#xD;
        traditional Chinese medicine treatment; 5) Subjects who needed systemic treatment with&#xD;
        corticosteroids (10 mg prednisone equivalent dose per day) or other immunosuppressants&#xD;
        within 2 weeks before the first use of the study drug were excluded from the use of&#xD;
        corticosteroids for local esophageal inflammation and prevention of allergy, nausea and&#xD;
        vomiting. Other special circumstances, need to communicate with the sponsor. In the absence&#xD;
        of active autoimmune disease, inhaled or topical corticosteroids and corticosteroids with&#xD;
        dose &gt; 10 mg / day prednisone were allowed to be used instead; 6) Those who have received&#xD;
        anti-tumor vaccine or received live vaccine within 4 weeks before the first administration&#xD;
        of the study drug; 7) Major surgery or severe trauma occurred within 4 weeks before the&#xD;
        first use of the study drug; 17. History of congenital or acquired immunodeficiency disease&#xD;
        or organ transplantation; 18. He had a history of allergy to monoclonal antibodies,&#xD;
        paclitaxel, cisplatin and other platinum drugs;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wang jia lei, doctor</last_name>
    <phone>18017312369</phone>
    <email>haitunqiao@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Xuhui</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wang jia lei, DOCTOR</last_name>
      <phone>18017312369</phone>
      <email>haitunqiao@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jialei Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

